AI Pathology Test Proves Effective for Black Patients and Late Recurrence Prediction

kjgeras · x · 2026-07-06

The model maintains strong predictive performance in the Black patient subgroup (C-index 0.72), where genomic tests have previously been reported to underperform. It also predicts late recurrence for HR+/HER2- patients (C-index 0.79), providing direct reference for extended endocrine therapy decisions.

Related event: Multimodal AI Pathology Test Outperforms Gold Standard in Breast Cancer Recurrence Prediction(11 posts)→

Original post →

More from Research

Research channel →